BACKGROUND Passive immunotherapy with convalescent plasma (CP) is a potential
treatment for COVID-19. Evidence from controlled clinical trials is inconclusive. METHODS We …

Evidence to support the use of steroids in coronavirus disease 2019 (COVID-19) pneumonia
is lacking. We aim to determine the impact of steroid use for COVID-19 pneumonia on …

Objective We aim to determine the impact of steroid use in COVID-19 pneumonia in-hospital
mortality. Design We performed a single-centre retrospective cohort study. Setting A …

Research Article A Multicentric, Open-Label, Randomized, Comparative Clinical Trial of
Two Different Doses of Expanded hBM-MSCs Page 1 Research Article A Multicentric, Open-…

Intravenous immunoglobulin (IVIG) use in non-approved indications, the increase in consumption
and its high cost recommend rationalisation in its utilisation. Aims To assess the use of …

Objectives 1. To assess the efficacy of Mesenchymal Stromal Cells (MSC) versus a control
arm as described in the primary endpoint. 2. To evaluate the effects of MSC on the secondary …

The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
variants of concern elicited by vaccination was evaluated in COVID‐19 …

Mesenchymal stromal cells (MSC) have immunomodulatory and tissue-regenerative
properties and have shown promising results in acute respiratory distress syndrome (ARDS) of …

Background COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2)
and causes substantial morbidity and mortality. At the time this clinical trial was planned, …

… Concepción Payares Herrera … Concepción Payares Herrera participated in writing the
paper and the data analysis and contributed analytic tools. … Concepción Payares Herrera …